BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21382020)

  • 1. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease.
    Shaw BE; Apperley JF; Russell NH; Craddock C; Liakopoulou E; Potter MN; Wynn R; Gibson B; Pearce RM; Kirkland K; Lee J; Madrigal JA; Cook G; Byrne JL
    Br J Haematol; 2011 Apr; 153(2):244-52. PubMed ID: 21382020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
    Oehler VG; Radich JP; Storer B; Blume KG; Chauncey T; Clift R; Snyder DS; Forman SJ; Flowers ME; Martin P; Guthrie KA; Negrin RS; Appelbaum FR; Bensinger W
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):85-92. PubMed ID: 15682068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
    Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.
    Garderet L; Labopin M; Gorin NC; Polge E; Fouillard L; Ehninger GE; Ringden O; Finke J; Tura S; Frassoni F
    Bone Marrow Transplant; 2003 Jan; 31(1):23-9. PubMed ID: 12621503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar outcomes of peripheral blood stem cells vs. bone marrow for human leukocyte antigen-matched unrelated donor transplantation in adult patients with acute myeloid leukemia using risk-adapted graft-versus-host disease prophylaxis.
    Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Eur J Haematol; 2014 Jul; 93(1):19-28. PubMed ID: 24527665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.
    Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE
    J Clin Oncol; 2004 Dec; 22(24):4872-80. PubMed ID: 15520055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
    Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
    Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
    Campregher PV; Hamerschlak N; Colturato VA; Mauad MA; de Souza MP; Bouzas LF; Tavares Rde C; Barros JC; Chiattone R; Paz A; Silla L; Vigorito AC; Miranda E; Funke VA; Flowers ME
    Eur J Haematol; 2015 Nov; 95(5):421-5. PubMed ID: 25645430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
    Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Shimoni A; Niederwieser D; Mufti GJ; Zander AR; Arnold R; Greinix H; Cornelissen JJ; Jackson GH; Craddock C; Bunjes DW; Ganser A; Russell NH; Kyrcz-Krzemien S; Rocha V; Mohty M
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1422-9. PubMed ID: 22446014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors.
    Bradstock K; Bilmon I; Kwan J; Blyth E; Micklethwaite K; Huang G; Deren S; Byth K; Gottlieb D
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1641-5. PubMed ID: 26079442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.